Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Operating Margin (2020 - 2025)

Rani Therapeutics Holdings has reported Operating Margin over the past 5 years, most recently at 584.19% for Q4 2025.

  • Quarterly results put Operating Margin at 584.19% for Q4 2025, up 87087.0% from a year ago — trailing twelve months through Dec 2025 was 2345.99% (up 284030.0% YoY), and the annual figure for FY2025 was 2345.99%, up 284020.0%.
  • Operating Margin for Q4 2025 was 584.19% at Rani Therapeutics Holdings, up from 6984.3% in the prior quarter.
  • Over the last five years, Operating Margin for RANI hit a ceiling of 1445.02% in Q2 2023 and a floor of 6984.3% in Q1 2025.
  • Median Operating Margin over the past 4 years was 268.13% (2021), compared with a mean of 530.28%.
  • Biggest five-year swings in Operating Margin: soared 538187bps in 2021 and later crashed -249163bps in 2024.
  • Rani Therapeutics Holdings' Operating Margin stood at 268.13% in 2021, then skyrocketed by 487bps to 1036.57% in 2023, then plummeted by -240bps to 1455.06% in 2024, then soared by 60bps to 584.19% in 2025.
  • The last three reported values for Operating Margin were 584.19% (Q4 2025), 6984.3% (Q1 2025), and 1455.06% (Q4 2024) per Business Quant data.